<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651703</url>
  </required_header>
  <id_info>
    <org_study_id>CYT004-MelQbG10 04</org_study_id>
    <nct_id>NCT00651703</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients</brief_title>
  <official_title>Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a specific cellular immune response in melanoma
      patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with
      different adjuvants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10 + Montanide</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10 + Montanide + Imiquimod</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10 + Imiquimod</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10 intra nodal injection</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmed Stage III or IV malignant melanoma

          -  HLA-A*0201 haplotype

          -  Expected survival of at least 9 months

          -  Willing and able to comply with all trial requirements (e.g. diaries, CTs)

          -  Given written informed consent

          -  Females only if non-reproductive or if they agree to consistently practice an
             effective and accepted method of contraception

        Exclusion Criteria:

          -  Any contraindication to any study related test or assessment

          -  Current or planned use of contraindicated concomitant medication

          -  Presence or history of relevant cardiovascular, renal, pulmonary, endocrine,
             autoimmune, neurological and psychiatric disease

          -  Infection with HIV, HBV or HCV

          -  Pregnancy or lactation or females planning to become pregnant during the study

          -  Abuse of alcohol or other drugs

          -  Use of investigational drug within 30 days before enrolment

          -  Previous participation in a clinical trial with a Qb-based Cytos vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ludwig Institute for Cancer Research; CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>CH-1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Klinik, UniversitätsSpital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>November 11, 2010</last_update_submitted>
  <last_update_submitted_qc>November 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Development</name_title>
    <organization>Cytos Biotechnology AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

